Australia markets closed

Allogene Therapeutics, Inc. (ALLO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.96+0.18 (+1.67%)
At close: 04:00PM EDT
11.25 +0.29 (+2.65%)
Pre-market: 08:35AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close10.78
Open10.78
Bid0.00 x 1800
Ask13.89 x 900
Day's range10.57 - 11.20
52-week range6.43 - 20.75
Volume1,371,292
Avg. volume1,670,762
Market cap1.576B
Beta (5Y monthly)0.63
PE ratio (TTM)N/A
EPS (TTM)-2.20
Earnings date02 Nov 2022 - 07 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est27.13
  • GlobeNewswire

    Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial

    ALPHA2 Trial, Evaluating ALLO-501A in Relapsed/Refractory Large B Cell Lymphoma Patients, is Designed to Leverage the Ease and Convenience of a Single Dose of ALLO-501AProtocol Supported by Clinical and Translational Data from Phase 1 Trial Indicating Deep Responses are Achievable with a Single Dose of ALLO-501A When Used with a Lymphodepletion Regimen That Includes an Optimized Dose of ALLO-647 SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: A

  • GlobeNewswire

    Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit

    SOUTH SAN FRANCISCO, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that management plans to present at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 6:30AM Pacific Time/9:30AM Eastern Time. The webcast will be posted to the Company's website at www.allogene.com under the Investors tab in

  • Zacks

    Allogene Therapeutics (ALLO) Down 10.9% Since Last Earnings Report: Can It Rebound?

    Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.